Before visiting, please review our current visitor policies and COVID-19 information.
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes (STRIDE)
This study is done to see if semaglutide has an effect on walking ability compared with placebo in people with peripheral arterial disease (PAD) and type 2 diabetes.
DiagnosisType 2 diabetes mellitus; symptomatic PAD with intermittent claudication
- Current or previous treatment with any GLP-1 receptor agonist (GLP-1-RA)
- Walking ability limited by conditions other than PAD
- Planned orthopaedic surgery in the legs, or other major surgery
- Vascular revascularisation procedure of any kind 180 days prior to the day of screening.
- Planned arterial revascularisation known on the day of screening.
- Recent myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack
- Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV.
Semaglutide vs placebo
For more information, visit the U.S. National Library of Medicine clinical trial database.
Key Participation Requirements
19 and older
Methodist Health System Trial Code